Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amikacin timing optimization in hemodialysis patients with end-stage renal disease
2014-001296-32Phase 4Active
- Sponsor
- FIBHULP
- Start
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of amikacin in bacterial disease (2 arms), sponsored by FIBHULP. Primary endpoint: Serum trough and peak comparison. Started May 2014; status: active.
02
Drugs
amikacin
03
Conditions
bacterial disease
Beyond the preview
Go deeper on 2014-001296-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001296-32.